Ankylosing Spondylitis Diagnosis and Treatment

Diagnostic Criteria and Treatment Guidelines

The American College of Rheumatology/Spondylitis Association of America guidelines recommend a treatment pathway for ankylosing spondylitis that includes first-line therapy with NSAIDs, conventional synthetic DMARDs for patients with peripheral arthritis, and TNF inhibitors for patients with active AS despite NSAIDs, with a confirmed diagnosis of AS being a critical prerequisite for TNF inhibitor therapy 1
The ASAS/EULAR recommendations state that anti-TNF therapy should be given to patients with persistently high disease activity despite conventional treatments, requiring a definitive diagnosis of AS 2
The American College of Rheumatology guidelines strongly recommend that TNF inhibitors should be used only after a confirmed diagnosis of AS and after failure of NSAID therapy, with the patient having either failed previous biologic therapy or had an inadequate response to at least two NSAIDs or have intolerance/contraindication to two or more NSAIDs 1

The American College of Rheumatology guidelines recommend considering alternative treatments while awaiting diagnosis confirmation, including continuing short-term prednisone for symptom control and considering physical therapy 1, 3
The use of TNF inhibitors without a confirmed diagnosis exposes patients to significant risks, including bacterial, viral, and opportunistic infections, malignancy, and lymphoma, highlighting the importance of completing diagnostic testing before considering TNF inhibitor therapy 1

The American College of Rheumatology guidelines recommend completing the diagnostic workup with MRI of SI joints and spine to confirm the diagnosis and rule out other conditions like osteomyelitis 1
The ASAS/EULAR recommendations emphasize the importance of a definitive diagnosis of AS before initiating anti-TNF therapy, which may involve MRI results and other diagnostic tests 2